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A. Toxemia of Pregnancy 
Hypertensive disorders of pregnancy are common complications of 
gestation involving six to seven percent of all late pregnancies and 
accounting for one fifth of the maternal fatalities in the United 
States each year."*" As a cause of perinatal death they are responsible 
for at least 25,000 stillbirths and neonatal deaths. 
The term toxemia is often used to refer to the acute hyper¬ 
tensive disorder specific to pregnant or puerperal women, although no 
toxin as such has ever been isolated. The classic term, eclampsia, 
is a Greek word used by Hippocrates to designate fever of sudden onset. 
Eclampsia means to "flash" or "shining forth" and is indicative of the 
fulminating character of the disease that has come to be known as 
eclampsia."*" Convulsions and coma which characterize eclampsia are not 
present in the entity known as pre-eclampsia, although they are identical 
in all other respects. Diagnosis is made on the basis of development 
of hypertension of 140/90 or an increase of 20/15 with proteinuria or 
edema (or both) after the twentieth week of gestation. It is 
predominantly a disease of young nulliparas, with other major predisposing 
factors including family history for eclampsia, multiple fetuses, diabetes, 
chronic hypertension and fetal hydrops. 
A number of hypotheses have been advanced in attempts to explain 
the etiology and pathophysiology of toxemia. Most have been either 

2 
discredited or disproven outright. The theory that ischemia of the 
uteroplacental complex somehow leads to hypertension and the other 
toxemic manifestations remains viable in both its ability to explain 
the diverse predisposing factors, and in the light of experimental 
work in a number of species including humans. 
B. Uteroplacental Ischemia 
2 
Young, in 1914, was the first to espouse the theory that toxemia 
was due to uteroplacental ischemia. He believed that the eclampsia 
and albuminuria of pregnancy were due to the liberation of products 
3 
of placental autolysis. In 1927, he noted a general resemblance 
4 
between toxemia and wound shock due to massive tissue damage. Beker 
proposed in 1929 that toxemia arose in those individuals in whom 
uterine resistance was abnormally large. He pointed out anatomic 
differences between uteri of primipara and multipara, injecting the 
uteri of cows with barium to demonstrate that the arteries of 
multipara were of markedly larger caliber. He felt that increases 
in systemic blood pressure in the toxemic state were necessary to 
overcome the abnormally high uterine vascular resistance. In 1948,^ 
he extended his studies with barium injections into human uteri including 
those of multipara, primipara and toxemics, again concluding that the 
toxemic state arose from a disturbance of hemodynamic equilibrium 
within the uteroplacental unit. 

3 
A similar formulation was expressed by Page and Ogden who felt 
that an inadequate maternal blood supply to the placenta led to the 
release of a vascular toxin which resulted in hypertension. Page^ 
was able to demonstrate pressor activity in a crude extract of placenta 
(although "depressor substances" were present in varying amounts). 
g 
Ogden et al., in 1940, created an experimental model in an attempt 
to demonstrate uterine ischemia as a cause of toxemia. They placed 
a clamp on the aorta below the level of the renal arteries in dogs. 
There was an increase in blood pressure in the pregnant animals but 
not in nonpregnant controls. They concluded that the products of 
conception were fundamentally responsible for the increase in blood 
pressure during the ischemic interval. The blood pressure elevation 
was reversible with removal of the clamp. 
9 
In 1949, van Bouwdijk Bastaanse and Mastbloom applied a 
Goldblatt clamp to the uterine arteries of dogs after ligation of the 
ovarian arterial collateral in order to produce ischemia of the uterus. 
Although chronic experiments resulted in abortion or premature delivery, 
blood pressure did rise acutely. They were not able to produce similar 
hypertension in nonpregnant animals. Van Bouwdijk Bastaanse"^ believed 
that toxemia was due to inability of the uterine arteries to meet demands 
for blood imposed by the growing uteroplacental unit. 
Gyongyossy and Kelenty^"*" experimented with dogs and cats, 
inserting baloons into gravid uterine horns. They found that increased 
intrauterine pressure led to an increase in systemic blood pressure. In 
addition, the distension of a human gravid uterus with Locke’s solution 
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led to an increase in blood pressure of 20-30 mm. 
12 
Berger et al. demonstrated in rabbits that placental ischemia 
(obtained by Z-sutures with atraumatic catgut through parts of the 
placenta) led to systemic hypertension. Uterine ischemia alone, 
i.e. placement of Z-sutures through the uterine wall excluding the 
placental insertion sites, did not lead to hypertension. Thus 
placental, and not uterine, ischemia appeared to be responsible 
for the hypertension. The studies were repeated by Berger and 
13 
Cavanagh in bilaterally nephrectomized rabbits with analogous results, 
indicating that the "pressor substance" was from the placenta. Using 
selective angiography they were able to demonstrate narrowing of the 
uterine, ovarian and renal arteries in response to the "pressor". 
The production of hypertension in the absence of the kidneys dealt 
a blow to the theories of Sophian^’ ^^ who suggested that 
toxemia was due to the stretching of myometrium producing a "utero- 
renal reflex". He submitted evidence that an increase in resistance 
to stretch of uterine muscle led to reflex inhibition of renal blood 
flow, leading to various degrees of renal cortical ischemia, resulting, 
in turn, in salt retention, hypertension and albuminuria. Additional 
disproof were the two cases of advanced extra-uterine pregnancy 
18 
complicated by toxemia reported by Benjamine and Craig and an ovarian 
19 
pregnancy described by Pride and Rucker which were strong evidence 
against the necessity for uterine distension. 
20 
Hodari was able to create chronic uterine ischemia by placing 
snug fitting Teflon bands on the uterine arteries of nonpregnant dogs. 
When the dogs became pregnant these bands prevented the vessels from 
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undergoing normal gestational hypertrophy, allegedly creating a situation 
of uterine ischemia. In banded dogs, hypertension and proteinuria 
developed, with resolution upon delivery. 
Toxemic states are known to occur in various species although 
none has a presentation precisely similar to human pre-eclampsia. 
21 
Anatomically and physiologically baboons are close to humans. Cavanagh 
placed hemoclips around the uterine arteries and ligated the ovarian 
arteries in baboons. In six animals the mean systolic/diastolic 
pressure was 170/115, while in 25 nonpregnant controls blood pressure 
was 140/90. Proteinuria was also present in the third trimester in 
the experimental animals. 
Evidence in humans also suggests the merit of the ischemia 
22 
hypothesis. Clementson demonstrated aortographically that of eight 
patients with severe or recurrent eclampsia, five suffered from hypo¬ 
plasia of the distal aorta. 
23 
Assali estimated uterine blood flow using the nitrous oxide 
method and found almost a 40% reduction in four cases of pre-eclampsia. 
24 
Browne and Veall injected radioactive sodium into maternal placental 
blood lakes and from its rate of disappearance calculated that the 
placental blood flow was reduced by 50% in pre-eclamptics, with 
comparable decreases in patients with uncomplicated hypertensive disease. 
25 
Similar studies were later performed by Landesman and Knapp. 
Suggestive evidence of impaired uteroplacental blood flow is 
2 6 
provided by studies by Gant et al. involving the metabolic clearance 
rate of dehydroepiandrosterone sulfate (DS). They demonstrated a decline 
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in DS clearance prior to the development of clinical toxemia. Clearance 
of DS from the maternal circulation depends on uteroplacental blood 
flow and conversion of DS to estrogens by the feto-placental unit. 
Since factors such as maternal liver steroid metabolism may influence 
27 
DS clearance, Madden et al. focused on placental conversion of DS 
to estradiol which is entirely a placental process. Again, DS 
clearance decreased before the clinical appearance of toxemia. These 
studies are important in that they suggest that toxemia may be 
diagnosed before the development of hypertension, edema, and 
proteinuria. 
The concept of an impaired uterine supply of blood helps explain 
the diverse predisposing factors in toxemia. The increased incidence 
among nullipara may be due to the fact that their vessels have not 
undergone previous gestational hypertrophy. In the case of multiple 
gestation, the overstretched uterine wall offers increased resistance 
to flow (similarly fibroid uteri, polyhydramnios, molar pregnancy). 
Hypertensive vascular disease is characterized by sclerosis of 
arterioles which might hinder the vasodilation necessary for adequate 
blood flow to the uterus. The fact that 5-15% of patients with 
chronic hypertensive vascular disease develop pre-eclampsia^ fits well 
with the ischemia theory. In women with long standing diabetes mellitus 
the uterine arteries are often calcified and such diabetics are especially 
28 




While the concept of uterine ischemia resulting in toxemia is 
a compelling one, the identity of the toxin remains obscure. The 
similarity to renovascular hypertension led many workers to explore 
the possibility that renin might be produced by the utero-placental 
unit resulting in hypertension. 
29 
Stakeman, in 1960, reported a renin-like pressor substance in 
30 
the placenta. Brown et al. demonstrated a renin-like enzyme in 17 
samples of human amniotic fluid collected near term. Since the 
concentration of enzyme was greater in the amniotic fluid than in 
the umbilical vein plasma and peripheral venous plasma of the mother, 
they concluded that it was likely that the renin-like substance was 
31 
formed or stored in intra-uterine tissues. Gross et al. studied 
rat uteri where they found high concentrations of renin. Ferris 
32 33 
et al. ’ isolated a pressor material from rabbit uteri and estimated 
that the renin concentration in the uterus greatly exceeded the 
concentration in the placenta. In addition they demonstrated that 
by weight, the rabbit uterus had three times the content of renin as 
the kidneys, and thus was a great potential source of renin. Ryan 
34 
and Ferris also reported the release of renin by the rabbit uterus, 
35 
while Gorden et al. showed that this renin was not responsive to 
the same physiological feedback mechanisms that normally decrease the 
concentration of renal renin. 
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The distribution of renin in human uteri was examined by Skinner 
36 
et al. who found that the distribution, with a low concentration 
in the myometrium and placenta and a high concentration in the 
chorion, was quite different from the rabbit. Conclusions by comparison 
to the rabbit are possibly erroneous due to different intrauterine 
distribution of renin. 
37 
Hodari and Hodgkinson nephrectomized dogs and demonstrated that 
plasma renin levels fell to nondectectable levels in 48 hours while 
in pregnant anephric dogs detectable values persisted through 72 hours. 
They suggested that under the stress of maternal bilateral nephrectomy, 
renin from the uteroplacental complex augments and perhaps compensates 
for maternal renin. A similar result was suggested by a report by 
38 
Capelli et al. who studied anephric patients. In four female patients 
considerable quantities or renin-like enzyme were found, but none in 
a male control, indicating the uterus as a possible source. At autopsy 
extraction and assay of adrenal, heart, ileum, liver, lung, ovary, 
submaxillary gland, stomach, thyroid, and uterine tissue demonstrated 
renin-like activity in only the uterine tissue. 
Early reports suggested that excess pressor material was in fact 
12 39 40 
present in the blood of patients with pre-eclampsia. ’ ’ In several 
41 42 43 44 
studies ’ ’ ’ it was discovered that in normal pregnancies 
there is an increase in renin levels above non pregnant values without 
hypertension. Even more interesting was the finding that in hypertensive 
pregnancies the renin concentrations were within a wide range found 
42 
at a comparable stage of normal pregnancy but that renin levels in 
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hypertensive patients with proteinuria were on the average less 
than the normotensives. Determination of renin concentrations in 
45 
placentas by Hodari et al. showed approximately equal concentrations 
in both toxemic and normal pregnancies. 
4 6 
Gorden et al. found that toxemics had lower levels of renin 
than did normals but presented evidence that during the middle trimester 
those women destined to develop toxemia responded with a higher mean 
47 
renin level under the stimulus of low salt diet. Tapia was unable 
to confirm these results as was Gorden in a follow-up study. According 
48 
to Talledo although there is a lower renin level among toxemic 
pregnancies, they are more sensitive to the effects of angiotensin 
which may compensate for the lower level. Along the same lines, 
49 
Abdul Karim and Assali demonstrated a decreased response to angiotensin 
during the course of normal pregnancy also suggesting that there may 
be fundamental difference in toxemics. 
In rabbits, Abernethy et al.^ demonstrated an increase in uterine 
venous renin from 1980±838 to 4320+1312 during uterine ischemia. 
Ferris et al.~^ also examined the role of renin in the physiology 
of pregnancy. Operating under the hypothesis that uterine renin 
functions as a regulator of uterine blood flow, they created uterine 
hypoperfusion by hemorrhage or by ligation of the uterine arteries 
in pregnant nephrectomized rabbits. They demonstrated a striking 
rise in the output of renin by the uterus, and increase in uterine 
blood flow as measured by radioactive microspheres, but inexplicably 
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a decreased blood pressure. A similar increase in uterine blood flow 
could be induced by administration of angiotensin and blocked by 
propranolol. 
The fact that renin levels increased in the Ferris study, but that 
the blood pressure decreased, is an interesting finding. It suggests 
that in addition to liberation of renin, the ischemic uterus may also 
have been liberating some vasodepressor such as prostaglandin. In 
addition, it suggests that during toxemia, although absolute renin 
levels are lower, there might be a deficiency of a vasodepressor 
substance (prostaglandin) which might account for the hypertension. 
D. Toxemia and Prostaglandins 
Prostaglandins are a group of cyclic fatty acids with diverse potent 
biological activities that were independently discovered in the early 
52 53 54 
1930's by Goldblatt, Kurzrok and Lieb, and von Euler. Von Euler 
further characterized the vaso-depressor and nonvascular smooth muscle 
stimulating effects of extracts of seminal vesicles and found their 
biologic activity to depend on an acidic lipid which he named prosta- 
55 56 57 
glandin. About 25 years later Bergstrom and coworkers ’ * 
isolated and determined the structure of a series of prostaglandin 
compounds from sheep seminal vesicles. (Figure 1) These were 
unsaturated hydroxylated ketonic derivatives of the parent 20 carbon 
five membered ring compound prostanoic acid. The prostaglandins of 
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Figure 1. Structures of commonly occurring prostaglandins 
the E class (PGE) were found to decrease blood pressure and stimulate 
nonvascular smooth muscle to contract. The prostaglandin F (PGF) 
compounds were without vasodepressor effects but had intestinal 
smooth muscle stimulating activity. 
Studies have demonstrated widespread occurrence of these compounds. 
They have been isolated, for example, from sheep seminal vesicles, 
sheep, pig and human lung, sheep and human semen, bovine brain, calf 
thymus, human menstrual fluid, and sheep iris. Biologic activity 
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includes contraction of the iris, stimulation of the gravid uterus, 
inhibition of gastric hydrochloric acid secretion and experimental 
ulcer production, bronchiolar relaxation, increased gastrointestinal 
58 
motility and inhibition of platelet aggregation. They may be 
extremely important local or systemic hormones mediating effects in 
virtually every organ. 
The presence of these potent vasodilators in the kidney focused 
59 
attention on their possible roles in renal blood flow auto-regulation 
and in the development of hypertension. In 1959, Bergstrom et al. 
55 
demonstrated that the infusion of PGE into humans resulted in lowering 
60 
of systemic blood pressure. Studies by Aiken and Vane revealed that 
angiotensin infusion lead to the release of prostaglandins which, in 
turn, blunted the vasoconstrictive effects of angiotensin within the 
61 
kidney. Induction of renal ischemia also led to elevated prostaglandin 
levels in both the ischemic and contralateral kidney in dogs. Other 
stimuli for release of prostaglandins from the kidney are renal 
. . . . 62, 63, 64, 65 . . . 64 
nerve stimulation and norepinephrine infusion. 
These studies suggest that prostaglandins serve to protect the kidney 
from decreased flow rates during stressful conditions that lead to 
renin release. Inasmuch as the ability of the kidney to synthesize 
PGE is great and the inhibition of the renal action of pressor 
hormones occurs at low concentration, a regulatory role for renal 
prostaglandin merits consideration. 
Relatively simple modifications of structure in the five membered 

13 
ring of prostaglandins may lead to striking changes in biological 
activity. In 1965, Lee et al.^ isolated three classes of vasoactive 
lipids from renal tissue. Prostaglandin and prostaglandin F 
had been previously characterized. The other substance was a potent 
vasodilator initially termed prostaglandin E-217 because of its 
chemical similarity to the E class of prostaglandins and its 
absorption peak at 217 millimicrons. Lee called this substance medullin, 
but it was later designated as prostaglandin (PGA^). Prostaglandins 
of the A series are derived from dehydration of the E series. PGA has 
little smooth muscle stimulation activity, but is a potent vasodilator 
67 
. . . . ,f- . 68,69 _ 
resulting m a hypotensive response on intravenous infusion. Its 
action is due to a direct effect on peripheral arteriolar beds 
.70 
without cardiac depression. 
Prostaglandin E is suited for local and not systemic action because 
although it is stable in the blood, it is rapidly inactivated on 
71 72 73 
passage through the lungs. ’ ’ Prostaglandin A on the other hand is 
not as rapidly inactivated and might function as a circulating antihyper¬ 
tensive substance in addition to its local effects. A role for 
prostaglandin A in the homeostatic mechanism for regulation of blood 
74 
pressure and sodium balance was postulated by Zusman et al. They 
demonstrated that circulating levels of PGA decrease during high 
sodium intake and increase during low sodium intake. The schema 
depicted in Figure 2 represents their hypothesis. Under conditions 
of low sodium intake plasma renin and angiotensin rise. Although 
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Figure 2: A possible mechanism for the control of 
prostaglandin A synthesis and release in 
response to alterations in sodium intake 

15 
increased levels of the potent vasoconstrictor angiotensin might be 
expected to elevate blood pressure, the increase in circulating 
prostaglandin A tends to normalize blood pressure. Since prostaglandin 
A stimulates aldosterone secretion^ the stimulus of angiotensin to 
conserve sodium and maintain intravascular volume is reinforced. The 
merit of this hypothesis is suggested through work by Zusman et 
7 6 
al. demonstrating that peripheral plasma levels of prostaglandin A 
in a group of patients with essential hypertension and in a group of 
patients with known renal artery stenosis were significantly lower 
than normal, 0.60+0.07 ng/ml and 0.69+0.07 ng/ml (mean ± standard error) 
respectively (normal 1.5±0.24 ng/ml). Perhaps a similar homeostatic 
mechanism for blood pressure might be present in the uterus as well. 
E. Prostaglandin and Trophoblastic Renin Mechanisms During Pregnancy 
Prostaglandins have been isolated from the menstrual fluid,^ 
human amniotic fluid, ^ and the umbilical cord,^ raising the question 
79 
of their physiologic role. In 1969, Ryan et al., using a bioassay, 
demonstrated that an acidic extraction of placenta produced relatively 
large amounts of a substance that relaxed the duodenum and decreased 
blood pressure in the rat. Using various criteria, this substance 
demonstrated chemical and biological characteristics similar to those 
of prostaglandin E. In addition, assay of four normal and four toxemic 




toxemic placentas than the normals. Alam et al. assessed PGE 
metabolism in placentas and found that it was decreased in toxemic 
placentas in direct proportion to severity of the disease. They 
suggested that although PGE does not appear to be a systemic hormone, 
it converts spontaneously to PGA which is more stable in the circulation. 
Therefore, faulty PGE metabolism might in turn lead to depressed levels 
81 82 
of PGA and result in hypertension, Russel et al. * evaluated 
3 3 
the ability of placentas to convert HPGE to HPGA. Normal tissue 
converted 100% of the PGE to PGA in five minutes. Under comparable 
assay conditions tissue preparations from eclamptic pregnancies 
converted less than 10% PGE. These results further indicate that 
impaired enzymatec formation of PGA could be characteristic of 
toxemia. 
8 3 84 
Speroff ’ has devised a comprehensive theory that incorporates 
the etiologic role of uterine ischemia and renin production with that 
of the antihypertensive effect of prostaglandin. He postulates a 
protective function of the uteroplacental unit, a concept similar to 
85 
that proposed by Browne some years earlier. 
According to Speroff, various factors that reduce blood flow through 
the uteroplacental unit stimulate the pregnancy to elaborate renin which 
moves into the maternal circulation and perhaps locally into the 
trophoblast to increase angiotensin levels (Figure 3). Increased 
peripheral resistance in the maternal circulation due to increased 





TROPHOBLAST ISCHtMlA Prostaglandins 
Figure 3: A hypothesis linking ischemia of the utero¬ 
placental unit and an aberration of the pregnant 
renin-angiotensin-prostaglandin system as a 
mechanism of toxemia. 
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Prostaglandins produced in the trophoblast in response to angiotensin 
may be responsible for maintaining decreased resistance to flow through 
the uteroplacental bed. The development of toxemia may represent defective 
prostaglandin production, loss of response to prostaglandin or a 
combination of these events. It is difficult to explain the 
decrease in circulating components of the renin-angiotensin system. 
Perhaps exhaustion of the system occurs similar to the apparently 
8 6 
exhausted situation in the sodium depleted rat. Finally, he 
postulates that the renal lesions of toxemia are explained by both 
vasospasm and the liberation of thromboplastin, due to relative 
ischemia of the uteroplacental unit that results in degeneration 
of trophoblastic tissue and release of thromboplastin. 
Some proof for Speroff's theory may be found in recent studies. 
8 7 
Franklin et al. infused angiotensin into Rhesus monkeys in the 
third trimester of pregnancy and noted a significant increase in the 
release of prostaglandin E into the uterine venous blood. These 
results suggest that the E prostaglandins play a uteroplacental 
role akin to that proposed for prostaglandins in the kidney. 
„ , 88 . . . 
Venuto et al. in an interesting series of experiments, 
demonstrated that male and nonpregnant female rabbits had lower 
arterial PGE concentrations than pregnant females, and calculated 
that uteroplacental secretion of PGE was greater than five times renal 
secretion. In addition, after inhibition of prostaglandin 
synthesis by intravenous administration of either meclofenamate or 

19 
indomethacin, uterine vein PGE levels dropped, uterine blood flow 
decreased, and blood pressure rose. 
While a prostaglandin based homeostatic mechanism as a factor 
in toxemia remains to be proven, the above evidence suggests that the 
uterus is a rich source of prostaglandin and that inhibition of its 
synthesis results in blood pressure elevation. 

20 
PURPOSE OF THIS INVESTIGATION 
83 84 
The intriguing theory proposed by Speroff 5 awaits definite 
proof at this time. Central to this theory is the concept that under 
conditions of uterine ischemia, the uteroplacental unit is capable 
of responding quickly through the elaboration of prostaglandin to 
maintain adequate blood flow through its vascular bed. 
Present evidence suggests that there is a biochemical defect in 
the placentas of toxemic women, but it is not clear whether this defect 
is reflected in systemic levels of prostaglandins. Studies in pregnant 
women were conducted in order to evaluate whether there were some 
clearcut difference in prostaglandin levels between toxemic and non- 
toxemic women, and in addition, whether absolute levels might vary over 
the course of pregnancy. 
Rabbit studies were designed to create a condition of acute uterine 
ischemia and to measure prostaglandin and renin levels in the uterine 
venous blood, as well as in the carotid arterial blood, in order to 
document a uterine source for prostaglandin. 
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MATERIALS AND METHODS 
A. Pregnancy Studies 
Pregnant patients who participated in this study were among those 
who received their prenatal care at the Yale-New Haven Hospital 
Women's Clinic. The study was approved by the Yale University School 
of Medicine Human Investigation Committee and all participants gave 
informed consent. 
During each prenatal visit a lOcc peripheral venous blood sample 
was withdrawn into a heparinized vacutainer evacuated tube. The 
sample was centrifuged at 2,000 rpm for 10 minutes, the plasma 
decanted into a 20 ml nylon vial, and the sample of plasma frozen 
at -20°C. 
Toxemia was defined for the purposes of this study as hypertension 
of 140/90 in previously normotensive patients which developed after 
the 24th week of pregnancy. 
B. Experimental Uterine Ischemia 
Studies were performed on 4-5 kg pregnant Australian white rabbits 
between the 26th-28th day of gestation. The animals were nephrectomized 
through bilateral flank incisions under anesthesia with nitrous oxide, 
and then kept without food or water. Twenty four hours later the 
animals were anesthetized with pentobarbital IV. A midline neck 
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incision was made for placement of a tracheostomy tube and for cannulation 
of one carotid artery with PE 160 polyethylene tubing. The carotid 
catheter was attached to a Statham transducer for continous monitoring 
of systolic and diastolic blood pressure on a Corometrics recording 
unit (Corometrics Medical Systems, Wallingford, Connecticut). 
The right femoral vein was exposed through an inguinal cutdown 
and cannulated with PE 160 polyethelene tubing. The catheter was 
advanced so that the tip was above the bifurcation of the vena cava, 
and attached to a Harvard constant withdrawal pump. The aorta was 
then exposed through a lower abdominal incision and a ligature 
passed around the aorta close to its bifurcation. Three five-minute 
baseline venous samples were withdrawn into heparinized syringes via 
the femoral cannula. Blood samples (5 ml) were replaced with an 
equal volume of 6% dextran in normal saline at the end of each 
withdrawal. The aorta was then ligated and four similar five minute 
samples drawn. At 17 1/2 minutes after ligation of the aorta, a 5 ml 
arterial sample was rapidly withdrawn from the carotid cannula, and 
its volume replaced with heparinized saline. Twenty five minutes 
after ligation, 10 mg Indomethacin (Merck, Sharp and Dohme) in l.Occ 
of bacteriostatic saline was infused through the carotid cannula 
and two additional five minute samples withdrawn from the femoral 
vein. 
Each blood sample was immediately divided into a 3.0 ml aliquot 
in a heparin anticoagulated vacutainer tube for prostaglandin determination 
and a 2.0 ml aliquot in an EDTA tube for assay of plasma renin activity. 
After centrifugation at 2,000 rpm for five minutes, the plasma fraction 

was drawn off with a pasteur pipette, placed in a 20 ml nylon vial and 
quickly frozen in a dry ice-methanol bath. Samples were kept 
frozen at -20° C. until the time of assay. 
C. Radioimmunoassay 
89 90 91 
The methodology is essentially that of Jaffe, ’ Caldwell, 
92 
and Zusman. Approximately 10,000 cpm of tritium labelled prostaglandin 
in 0.1 ml of buffer was added to 1.0 ml of plasma to serve as tracer 
for recovery. The sample was then acidified to pH 3.5-4.0 with 0.1 
ml of 0.5 N HC1 and vigorously extracted with 7.0 ml of redistilled 
ethyl acetate (Mallinckrodt, analytical reagent). Chromatographic 
separation was carried out using 0.5 mg of silicic acid heat activated 
for one hour at 130° C, and packed into Brock minicolumns (1.0 x 15.0 
cm glass, Macalaster-Bicknell, New Haven, Connecticut). After the 
sample was applied to the columns extraneous lipids were eluted with 
1.0 ml of benzene and the eluate discarded. A solvent system of 
benzene- ethyl acetate-methanol was used to elute the various classes 
of prostaglandin. Spectro quality reagents were used fresh and the 
ethyl acetate redistilled. The chromatography is unable to separate 
prostaglandins within a particular class (eg. PGE^ from PGE^). The 
elution pattern is shown in Figure 4. 
The assay was performed in 10 x 75 mm glass disposable culture 
tubes. Stock solutions of prostaglandin were aliquoted in triplicate 
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ELUTION PATTERNS OF PROSTAGLANDINS A.B.E B F 
VIA SILICIC ACID COLUMN CHROMATOGRAPHY 
SOLVENT BEN j BENZENE / 
SYSTEM ZENE ETHYL ACETATE 
60/40 
BENZENE / 
ETHYL ACETATE / METHANOL 
60/40/2 
BENZENE/ 
ETHYL ACETATE /METHANOL 
60/40/20 
Figure 4 
through a concentration gradient of 0.1 to 2.0 ng. Prostaglandin 
fractions from the column were dried, dissolved in ethanol, aliquoted 
into culture tubes, and dried. A 10% fraction was aliquoted for 
estimation of recovery. Antisera and approximately 10,000 cpm 
tritiated prostaglandin were added to the tubes which were allowed 
to equilibrate for at least two hours at 4°C. 
One ml of a buffer solution containing 0.25% charcoal (Norit A) 
and 0.025% dextran was added within 30 seconds to all tubes in the assay 
and three minutes later the tubes were centrifuged at 1200 g for five 
minutes. The supernatant was decanted directly into a 20 ml 
scintillation vial and 7.0 ml of Riafluor (New England Nuclear) added. 
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Radioactivity was determined in a Packard Scintillation Counter, 
Model 3375, or a Nuclear Chicago Scintillation Counter. Sample 
values were calculated using a logit plot with linear regression 
analysis. 
Validation of assays for precision has been carried out by 
measuring increasing amounts of prostaglandin added to a known 
low level plasma pool. For assessment of reproducibility plasma pool 
containing low and high prostaglandin concentrations were run with each 
assay. The coefficient of variation between (inter) and within 
(intra) assay reproduction has been about 10%. 
D. Renin Assay 
Plasma renin activity was determined by measurement of angiotensin I 
generated in vitro. After adjustment of 1.0 ml aliquots to pH 6.0 
with 0.2 M maleate buffer, duplicate aliquots were incubated in the 
presence of converting enzyme and angiotensinase at 37°C or 4°C for one 
hour. All samples incubated at 37° were then matched with their 4° 
controls, and the angiotensin I measured by radioimmunoassay in a 
93 
modification of the Haber method. Materials used were those supplied 
125 
in the angiotensin I ( I) Radioimmunoassay Kit of the New England 
125 
Nuclear Corporation. Separation of bound and free angiotensin I ( I) 
was achieved by differential absorption of free antigen on activated 
charcoal followed by centrifugation. Values were corrected using the 
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amount measured in the 4°control. Samples and plasma renin activity 
was expressed as mg angiotensin I formed per ml per hour. The 
lower limit of sensitivity of the assay is 0.01 - 0.02 ng 
angiotensin I. 
E. Statistical Methods 
The age, weight, and weight gain for the toxemic group and the 
nontoxemic group were compared using the Student's t-test. To 
determine change in prostaglandin concentration over time a linear 
regression analysis was performed to determine slope i.e. linear 
regression coefficient (b) and standard error of the slope (S^) for 
each subject. In order to compute the regression coefficient for 
the entire group, the toxemic, and non-toxemic groups, a weighted mean 
was found using the following equation: 
“ - 11 sb2 
b = Emb 
E a) 
where: 03 = weight and b = weighted mean regression coefficient. The 
groups were then compared using a t-test for differences in means 
94 
for independent samples. The mean prostaglandin concentration for 
each group were also determined by similar method of weighted means. 
For prostaglandin A, the concentration at any particular week (x) 
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was determined using the following equation: 
y = y + b (x - x) 
where: y = predicted PGA, y = weighted mean PGA, b = weighted 
regression coefficient and x = weighted mean weeks. 
Differences between the toxemic and non-toxemic group were 
then determined by applying 95% (and 99%) confidence limits to each 
of the predicted values and determining whether the ranges for either 




A. Pregnancy Studies 
Table 1 presents the age, parity, race, weight (initial and weight 
gain), blood pressure (average and maximum), complications, and mean 
concentrations of PGF, PGE, PGA. Twenty five women participated 
in the study with assays performed on 170 samples, although only 15 
subjects (105 samples) were assayed for PGA because of assay difficulties. 
Six patients became toxemic according to the criteria of blood pressure 
elevation greater than 140/90 after the twenty fourth week of pregnancy. 
Since the criteria were designed to distinguish a hypertensive 
condition specific to pregnancy the single patient with chronic 
hypertension (JK) was grouped with the non-toxemics for purposes of 
analysis. Her hypertension was present before and persisted after 
the period of her pregnancy, and she demonstrated neither the edema 
nor the proteinuria which often accompany toxemia. 
The mean age of the entire population was 21.36 ± 4.42 years. The 
mean age for non-toxemics was 21.42 ± 4.95 and for toxemics was 21.17 
± 2.32, with no statistically significant difference between the groups. 
All the toxemics were primigravida, while 15/19 of the non-toxemics 
were also primigravida. In the toxemic group there were two whites, 
two blacks and one Puerto Rican. The mean weight for the entire group 
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toxemics 129.50 ± 61.61 also without statistical significance. 
The toxemic group gained 28.33 ± 13.79 pounds while the non-toxemics 
gained 24.89 ± 13.54 pounds. Again there was no difference between 
the groups. 
Of the six members of the toxemic group, three had edema (DA, 
ME, BB), one had proteinuria (BB), one was a class A diabetic (LA), 
and another had a borderline GTT (DC). 
Appendix A contains the level of prostaglandin A, E, and F for 
each woman along with the pregnancy week which it represents. The 
mean, standard deviation(SD), regression coefficient(b), and the error 
of the slope (S, ) are also included. It will be noted that there 
b 
are few samples before the 20th gestational week. 
The weighted mean linear regression coefficients are shown in 
Table 2. For PGE the weighted mean slope was -17.27 ±1.92 with a slope 
of -17.41 ± 1.99 for the non-toxemics and -15.83 ± 7.30 for the toxemics. 
The slope for the entire group was significantly different from a line 
of zero slope (p <.001), indicating that prostaglandin E levels 
decreased as the pregnancy approached term. There was no significant 
difference between the non toxemic and toxemic groups. 
For PGF the weighted mean coefficient was -4.04 ± 0.84 with a 
value of -4.27 ± 0.86 for the non-toxemics and 0.49 ± 3.74 for the toxemics. 
Again the slope for the whole group was significantly different from 
zero (p < .001), and without any difference between non-toxemics and 
toxemics. 

CHANGE IN PROSTAGLANDIN CONCENTRATIONS DURING PREGNANCY 
(± SEN) 
MEAN NONTOXIC TOXEMIC 
PGA -6.7H1.92 -9.81 ±1,55 2.77±2.69 
PGE -17.41±1.99 -17.41±1.99 -15.28±7.30 
PGF -4.04±0.84 -4.27±0.85 0.42±3.74 
TABLE 2: Weighted mean linear regression coefficients representing 
change in prostaglandin concentration over time. For PGA 
mean n=15; riontoxic n=ll; toxemic n=4. For PGE and PGF: 
mean n=25; nontoxic n=19; toxemic n=6. 
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The weighted mean slope for PGA was -6.71 ± 1.92 for the group 
as a whole (P < .001, compared to zero slope). For the toxemics 
slope was 2.77 ± 2.69 and for non-toxemics -9.84 ± 1.55. The slope 
for the toxemics was significantly different from the non-toxemics 
(p < -05). 
In those instances in which the regression coefficient (or 
slope) for the toxemics was essentially equal to that for the non- 
toxemics one may then determine the y-intercept (prostaglandin 
concentration in pg/ml plasma) for each group. Analysis of the result 
will then determine whether the identical slope represents the same 
line or parallel lines. 
Table 3 presents the weighted mean concentrations of prostaglandin 
for the various groups. For PGE and PGF there was no significant 
difference in weighted mean prostaglandin concentration between the 
toxemic and non-toxemic group. Because the regression coefficients 
for these groups were also the same one can conclude that the 
groups are essentially the same in both the level of PGE and PGF and 
change over time. 
For PGA the weighted means are essentially the same for the non- 
toxemic and the toxemic group, but since the regression coefficient 
for these groups differ, in order to compare the values, one must 
compare them week by week. The mean level in Table 3 might represent 
a point near the intersection of the regression lines and thus 
obscure differences which might exist at the beginning of 
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PROSTAGLANDIN CONCENTRATIONS DURING PREGNANCY 
MEAN NONTOXIC TOXEMIC 
PGA 477.97±24.24 477.92±35,75 478.02+32.98 
PGE 853.82±47.80 843.02±51.58 919.45±127.2 
PGF 299.38+15.23 295.94±16.28 323.41±43.01 
TABLE 3: Prostaglandin concentration in pg/ml plasma. For PGA: 
mean n=l05; nontoxic n=73; toxemic n=27. For PGE and PGF: 
mean n=170; nontoxic n=130; toxemic n=40. 
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pregnancy or close to term. Table 4 gives PGA levels at several different 
weeks for the non-toxemic and the toxemic group, and demonstrates 
that at 20, 25 and 40 weeks the groups are significantly different 
(p < .001). It appears, therefore, that before the 25th week the 
toxemics have lower levels of PGA than their non-toxemic counterparts, 
but that as the 30th week approaches the difference is gradually 
effaced. After the 35th week the toxemics exceed the non-toxemics 
achieving a highly significan difference by the 40th week. 
B. Experimental Uterine Ischemia 
The results of experiments in pregnant rabbits are shown in 
Figures 5-9, which demonstrate blood pressure, plasma renin 
activity, and prostaglandin concentrations in uterine venous and carotid 
arterial blood. In addition, experimental interventions of aortic 
ligation and indomethacin infusion are depicted. 
Following aortic ligation the blood pressure rose in all 
experimental animals. Maximal blood pressure was statistically 
above baseline values (p < .005). Pulse pressure, in general, was 
unchanged throughout. There was no evident change in the rate of 
blood pressure rise following indomethacin infusion. 
There was no consistent change in plasma renin activity 
following either aortic ligation or indomethacin infusion. Similarly, 
there was no characteristic difference between arterial or venous 
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WEEK TOXEMIC NON TOXIC P VALUE 
20 447.49 616.78 .001 
25 461.26 567.59 .001 
30 475.12 518.41 MS 
35 488.98 469.22 NS 
40 502.83 420.04 .001 
Table 4: PGA concentrations (pg/ml) at given gestational 
weeks for toxemics and nontoxics (NS=not significant) 



















Figure 6- Effect of aortic ligation and indomethacin infusion 
on prostaglandin concentration, plasma renin activity 
and blood pressure in the pregnant rabbit. 
"Archemedes" 






















Figure 6: Effect of aortic ligation and indomethacin infusion on 
prostaglandin concentration, plasma renin activity 




























Figure 7- Effect of aortic ligation and indomethacin infusion 
on Drostaglandin concentration, plasma renin acitvity 
and blood pressure in the pregnant rabbit. 
"DaVinci" 
MINUTES 






















Figure 8- Effect of aortic ligation and indomethacin infusion 
on prostaglandin concentration plasma renin activity 
and blood pressure in the pregnant rabbit. 
"Einstein" 





















Figure 9: Effect of aortic ligation and indomethacin infusion 
on prostaglandin concentration, plasma renin activity 
and blood pressure in the pregnant rabbit. 
-15 -10 -5 0 5 10 15 20 25 30 
ligation indomethacin 
MINUTES 




The concentrations of PGE, PGA and PGF did not demonstrate any 
consistent change following aortic ligation. Indomethacin infusion 
did not produce characteristic change in prostaglandin levels. The 
arterial concentrations approximated their venous counterparts. PGE 
levels in two animals (Copernicus, DaVinci) were extremely high, 
averaging about 20 ng. 
All the experiments were complicated by meconium staining of the 




A. Pregnancy Studies 
In analyzing the epidemiological data from Table 1, it is apparent 
that the toxemics and non-toxemics were essentially identical with 
respect to age, weight, and weight gain. All the toxemics were 
primigravida which is consistent with the increased incidence of 
this disorder among nullipara, but a large proportion of the non- 
toxemics in the study were also primigravida. The identity between 
the toxemic and non-toxemic groups for the above characteristics 
assures that any differences in prostaglandins are not due to these 
factors. 
The purpose of this study was to determine if there were some 
difference between toxemic and non-toxemic women with respect to 
prostaglandin concentration which might account for their elevated 
blood pressure, and in addition, to document any change in prosta¬ 
glandin level as the pregnancy approached term. 
95 
Challis et al. measured PGF in the peripheral plasma during 
the final trimester of pregnancy in rhesus monkeys. They found that 
the concentration of PGF in femoral venous plasma was highly variable 
in serial samples taken from the same animal and in samples from 
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different animals at the same time of gestation. They observed 
no increase in plasma concentration of PGF prior to labor however. 
96 
Guitterez-Cernosek et al. found that in humans PGF gradually rose to 
a peak in the second trimester (17-20th week) and then declined 
to non pregnant levels. They also followed nine patients and found a 
97 
similar pattern of decline in PGF levels. Brummer on the other 
hand, found that levels during the second trimester were not different 
than mean levels during the third trimester. In another study, 
98 99 
Brummer found high levels during labor. Karim found that PGF 
concentrations were not detectable in the plasma of pregnant 
women except at the time of labor. Table 5 represents the experience 
of several investigators who studied prostaglandin levels at various 
stages of pregnancy. 
The present study is the largest to date with 25 women and 170 
samples. The data analysis is also more sophisticated. Because 
each study subject was not assayed at the same pregnancy week, if 
means were calculated for each week or group of weeks there would 
be unequal representation and the possibility of spurious results. 
Instead, a linear regression analysis was performed for each 
subject and then a weighted mean regression coefficient was calculated 
to determine change over time. There are several distinct benefits to 
this treatment of the data. First, the plasma samples for each woman 
were assayed in the same lot, and a regression slope for each subject 
computed. As a result any interassay variability, however slight, is 
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Table 5: The experience of several investigators who examined changes 






eliminated. In addition, the variability in prostaglandin concentration 
95 
that was noted by Challis et al. and which may be due to the fact 
that prostaglandins are released in spurts^^ is corrected for by the 
weighting maneuver. By performing a weighted regression and a 
weighted mean, points which deviate greatly from the others are 
given less emphasis. Finally, in those intances in which the regression 
slope for toxemic and non-toxemic women are different, one may then 
calculate the prostaglandin concentration at a specified 
gestational week. If one were to simply calculate a mean concentration 
for each group one might obscure actual differences because the mean 
fell at the intersection of the two regression lines. It is clear, 
therefore, that the method of analyzing changes in prostaglandin 
concentration in each woman over the course of pregnancy is more 
advantageous than simply finding the mean concentration for all 
women at any specific time. 
The results of this study demonstrate that for both PGE and PGF 
there is a decline in concentration as term approaches. The 
significance of such a change is not readily apparent. Jubiz 
and Frailey^^ have shown that PGE levels increase in plasma sample 
that have been stored frozen, presumably due to the synthetic 
activity of platelets which are not removed entirely when the blood 
is centrifuged. If the phenonmenon which they described is real, 
the blood collected earlier in pregnancy would have been stored longer 
resulting in spuriously elevated levels initially with a gradual 

decline. A similar study has been performed by Pletka and Hickler 
who found that there was no change in PGA concentration in frozen 
plasma samples. 
102 
The slope for PGA between the toxemic and the non-toxemic group 
are significantly different (p < .05) and comparison of absolute 
concentrations of PGA early in pregnancy and at term are significantly 
different (p < .001). Although the data is significant, the results 
are based on only four toxemic subjects (27 samples) and must therefore 
be viewed with some circumspection. In addition, the weighted regression 
tends to obscure the fact that there was large variation in regression 
coefficient for the toxemic group (range -41 to +9) and thus the results 
are not diagnostic in any clinical sense. 
In order to determine whether pregnancy represents a unique situation 
in terms of prostaglandins, one might wish to compare the concentration 
of various prostaglandins in nonpregnant females and in males to those 
of pregnant women. Table 6 demonstrates the data of several investigators 
, , , . 74, 103, 104, 105, 106, 107, 108, 
who measured prostaglandin concentrations 
109, 110 t^e stuc[ies there is considerable range, and values from 
different laboratories also demonstrate a considerable range. Normal 
prostaglandin concentration in venous blood, by radioimmunoassay, if 
there are indeed normal values, are not agreed upon at the present time. 
Aside from the assay difficulties and the intermmittent nature of 
their secretion, PGE and PGF are largely metabolized in the lungs?^’ 
72 73 
* In addition, the synthesis of prostaglandins is inhibited by 

H / 
"Normal" Prostaglandin Concentrations in Humans 
Reference PGF PGE PGA # Subjects 
74 380 250 1600 7 
103 870m 690m 35Cm 14 
103 770f 680f 320f 6 
104 730m 1480m 6 
104 820f 177 Of 5 
105 84m 378m 1024m 10 
105 154f 316f 888f 16 
106 500m 12 
107 134 5 
108 4030* 430* 8 
109 230 260 420 12 
110 231m 54 
no 502m 65 
no 420m 30 
present 
study 
299* 853* 170 
477* 105 
Table 6: Reported prostaglandin concentrations in pg/ml. m=male; 
f=female-s *=pregnant female. 
anfci'iuM nr an or i si j noono nrhnfif 
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. . Ill, 112, 113 . ...... 
aspirin and although patients were hopefully not taking 
aspirin, the drug is present in so many formulations that it may 
have been ingested by the study subjects. Finally, there may be 
103 
other variations produced by diurnal cycle, diet, activity and 
psychological factors that contribute to the broad range found in 
this and in other studies. One must question, therefore, whether 
systemic levels of prostaglandins mean a great deal. There appears 
to be little point in comparing studies performed in different 
laboratories. The major use at the present time for prostaglandin 
assay is to determine changes over time or as the result of some 
experimental manipulation. 
In summary, these studies have failed to detect any difference 
in PGE or PGF concentration between toxemic and normal pregnancies. 
PGA concentrations were statistically different between the two groups 
but the population was small and conclusions should not be made on the 
basis of the data. The concentration of PGE and PGF appeared to 
decrease as term approached. Prostaglandins may,in fact, be mediators 
of uteroplacental blood flow regulation, and although there might 
be some abnormality ifi such a homeostatic mechanism in toxemics, this 
study was unable to detect any such derangement by assaying systemic 
concentrations of prostaglandins. 
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B. Experimental Uterine Ischemia 
These studies were performed in the hopes of demonstrating an 
increase in prostaglandin concentration following experimental uterine 
ischemia produced by ligation of the aorta in pregnant rabbits. 
In order to demonstrate such a change, samples were drawn from the 
inferior vena cava to asses variation in prostaglandin production 
by the uterus. The samples were drawn over five minute intervals 
since there is evidence in Merino ewes that prostaglandins may by 
released in spurts. jn addition, carotid arterial samples were 
taken in order to document a uterine source for prostaglandins. 
Similar experiments by Ferris et al.~^ suggested that blood pressure 
fell following experimental interventions which decreased uterine 
blood flow, raising the possibility that prostaglandins might be 
liberated in this situation. If this were indeed the case, one might 
then extrapolate from experimental uteroplacental ischemia to human 
toxemia and postulate some defect in prostaglandin release to 
, , 83, 84 . 
account for hypertension as suggested by Speroff. Rabbits 
were nephrectomized 24 hours before the experiments since rabbit 
114 
kidney has been shown to be an abundant source or prostaglandin. ’ 
115, 116, 117 
Following ligation of the aorta, the blood pressure rose in all 
the experimental animals. One might expect some increase in blood 
pressure since the ligature produces an increase in peripheral resistance. 

50 
One would not, however, expect a gradual and inexorable rise over 
thirty minutes as was noted. Blood was replaced cubic centimeter 
for cubic centimeter with 6% dextran in normal saline. There is 
no reason to suspect that fluid overload produced the elevation of 
blood pressure. There was not an elevation in renin concentration 
nor a depression in prostaglandin which could account for the blood 
pressure rise, and there was no change following indomethacin infusion. 
There was no rise in plasma renin activity following aortic 
ligation which is at variance with similar studies by Ferris et 
al.^ where uterine artery ligation produced striking elevations in 
renin. Although the fetuses were not viable at the conclusion of 
the experiment there was no initial rise in renin following ligation 
as one might have expected. 
By ligating the aorta blood flow is decreased to the hindlimbs 
as well as the uterus. Aiken and Vane^ demonstrated that the 
hindlimbs did not produce prostaglandins under conditions of 
angiotensin induced vasoconstriction. They suggested that 
prostaglandin production served a specific mechanism to protect the 
kidney from decreased flow, and a similar mechanism might also 
operate in the uterus. 
Our experiments showed no consistent change in prostaglandin 
concentration following aortic ligation. There was no difference 
between arterial and venous prostaglandin concentration, but arterial 
samples were drawn 17 1/2 minutes following ligation, and it is not 

51 
clear whether some transient change in uterine prostaglandin production 
may have occurred earlier. It is not known at what point the fetuses 
died, or the effect of their demise on blood pressure, renin or 
prostaglandin. 
Evidence suggests that prostaglandins are not stored but are 
produced by specialized cells from locally available arachidonate^^ ’ 
In the kidney these lipid laden renomedullary interstitial cells, 
situated between vasa recta, Henle’s loop and the collecting duct. 
have been shown to produce prostaglandins when grown in tissue culture 
121 
Similar cells have not been demonstrated in the uterus, but the 
88 
capacity of this organ to produce prostaglandins in quantity suggests 
that such cells might exist in the uterus as well. 
Because prostaglandin concentration did not change during the 
course of acute uteroplacental ischemia one might advance the hypothesis 
that late in gestation prostaglandins are maximally produced from 
precursors in order to protect the products of conception from 
compromised blood flow. This hypothesis is consistent with 
120, 
evidence that the uterus is an abundant source of prostaglandin, 
88 
and that inhibition of prostaglandin leads to elevation of maternal 
blood pressure and decrease in uterine blood flow."^ If one were to 
create chronic uteroplacental ischemia one might be more successful 
in demonstrating a difference in prostaglandin production by the uterus. 
Although these studies do not afford proof of a defect in the 
prostaglandin system as a causative factor in toxemia, if prostaglandins 
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are in fact maximally produced as hypothesized, an abnormality late 




A. Pregnancy Studies 
1. There was no statistical difference between toxemic and nontoxemic 
women in regard to mean concentration of PGE and PGF. While there 
were statistically significant differences in PGA concentrations 
the small sample size precludes any definite conclusions. 
2. Both PGE and PGF concentrations decreased as pregnancy approaced term. 
3. Caution should be exercised in interpreting peripheral venous 
prostaglandin concentration values. 
4. Inter-laboratory comparisons of prostaglandin concentrations are of 
little value. 
B. Experimental Uterine Ischemia 
1. Following aortic ligation blood pressure rose. 
2. No elevation in plasma renin activity was demonstrated. There was 
no difference between arterial and uterine venous concentrations of 
renin. 
3. Neither aortic ligation nor indomethacin infusion resulted in 
consistent change in prostaglandin concentration. Uterine venous 
concentration did not exceed arterial concentration 17 1/2 minutes 
following aortic ligation. 
4. Prostaglandin may be maximally produced by pregnant uteri close to 




Prostaglandin Concentration by Week for Pregnant Humans 
Subj ect Week PGF PGE PGA 
1. DA* 25 594 714 1024 
29 320 842 652 
31 217 384 410 
34 485 507 386 
36 182 249 377 
37 236 270 429 
38 155 312 449 
39 237 329 276 
mean 290 450 500 
S.D, 170 219 236 
slope -23.6 -37 -41.6 
Sb 
10.46 10.25 10.01 
2. EB 19 248 652 536 
26 359 670 367 
30 220 225 353 
32 259 446 412 
34 231 283 402 
38 220 264 337 
mean 256 423 401 
S.D. 52 199 72 
slope -3.19 -23.9 -8.3 
Sb 
3.63 8.97 3.47 
3. PG 23 766 1819 1405 
33 971 1731 830 
35 495 1486 920 
36 529 1769 1025 
37 646 1757 951 
38 508 1280 817 
39 529 1482 851 
mean 634 1617 966 
S.D. 177 202 210 
slope -4.61 -2.4 2.53 
sb 
4.88 5.95 6.17 
S.D = Standard Deviation Slope = Regression Coefficient * = 








Week PGF PGE PGA 
15 497 1029 556 
19 327 836 449 
29 416 1060 513 
34 295 591 285 
36 648 1004 394 
38 245 760 354 
39 298 879 433 
mean 389 879 426 
S.D. 142 168 92 
slope -3.23 -6.09 -6.54 
sb 
6.52 7.42 3.20 
22 294 1090 1006 
24 344 885 1357 
32 333 1035 741 
34 227 978 998 
36 201 701 847 
37 271 664 931 
mean 272 872 980 
S.D. 54 169 209 
slope -5.63 -18.39 -18.23 
Sb 
2.84 8.53 24.26 
27 648 1515 642 
32 593 1948 497 
34 409 1358 655 
36 515 1801 594 
37 428 1483 460 
38 482 1347 531 
mean 512 1575 554 
slope 93 245 77 
S.D. -18.02 -12.95 -4.8 
sb 
7.18 29.6 4.93 
. 1 
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Subj ect Week PGF PGE PGA 
7. PC* 19 477 1256 758 
23 384 966 766 
25 438 1287 572 
27 540 1141 530 
30 145 558 342 
34 241 647 424 
35 237 684 621 
37 689 1441 776 
mean 393 998 598 
S.D. 180 334 164 
slope -2.96 -15.5 -6.86 
Sb 
11.53 20.58 10.15 
8. DV 32 330 921 565 
36 259 838 591 
37 2 73 1252 542 
38 342 769 588 
39 265 843 591 
40 287 852 420 
mean 292 910 549 
S.D. 35 175 66 
slope -4.4 -10.8 -9.65 
Sb 
5.79 30.14 10.69 
. LA* 19 234 911 426 
25 488 1178 436 
28 251 864 410 
29 267 1008 514 
34 398 1400 638 
38 300 1722 548 
mean 321 1180 495 
S.D. 98.1 330 88 
slope 1.89 40.36 9.81 
sb 
7.31 14.26 4.4 
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Subj ect Week PGF PGE PGA 
10. JC 16 478 2197 1143 
28 366 1026 636 
30 332 651 448 
32 247 766 338 
33 309 736 469 
37 336 634 461 
mean 344 1001 583 
S.D, 76 602 291 
slope -8.7 -79.53 -37.2 
Sb 
3.01 12.92 7.89 
11. DC* 25 312 1284 374 
28 395 1065 473 
30 260 887 450 
35 263 699 437 
37 281 1351 481 
mean 302 1057 443 
S.D. 56 271 42 
slope 5.91 -9.02 5.31 
Sb 
5.55 31.25 3.88 
. JK 31 270 761 351 
34 220 576 453 
35 309 823 667 
36 229 330 323 
37 182 402 291 
39 178 311 299 
mean 231 533 379 
S.D. 51 222 145 
slope -12.4 -61.9 -14.8 
sb 
6.9 26.2 25.4 

58 
Subj ect Week PGF PGE 
13. CS 14 442 1320 
15 195 445 
17 204 716 
19 288 837 
27 628 1597 
33 819 1918 
35 290 1116 
37 163 684 
mean 378 1078 
S.D. 235 504 
slope 5.75 18.06 
sb 
9.83 20.34 
14. CT 19 123 1042 
23 355 1205 
25 396 1157 
29 204 586 
30 150 470 
37 124 538 
38 129 388 
39 259 612 
mean 205 749 
S.D. 109 329 
slope -5.58 -22.5 
sb 
2.90 6.26 
15.IB 29 383 1636 
31 241 735 
33 250 746 
36 201 720 
37 223 985 
39 273 1173 
40 217 793 
mean 255 969 
S.D. 61 337 





Subj ect Week PGF PGE 
16.ME* 26 417 2501 
31 391 1776 
34 1363 910 
36 1752 1062 
37 1148 981 
38 747 901 
39 930 1482 
mean 961 1373 
S.D. 496 596 
slope 56.9 -101.4 
sb 
41.26 33.63 
17. LT 23 2134 2067 
30 384 1058 
33 214 743 
36 192 438 
37 335 967 
38 335 609 
39 409 1015 
40 405 595 
mean 551 936 
S.D. 633 508 
slope -89.5 -73.5 
sb 
28.5 20.87 
18, DB 18 627 X 
23 666 1694 
28 481 991 
36 395 1105 
38 921 874 
mean 618 1166 
S.D. 202 364 





Subj ect Week PGF PGE 
19. JF 21 403 892 
28 412 794 
33 368 618 
34 448 653 
35 511 722 
mean 428 736 
S, D. 54 116 
slope 1.31 -16.88 
sb 
2.08 5.04 
20. BB* 18 437 X 
22 459 1629 
25 292 1332 
26 270 1078 
27 285 1202 
29 648 2050 
mean 398 1458 
S.D. 147 389 
slope 2.47 17.47 
sb 
18.64 97.05 
21. LG 28 747 909 
29 354 373 
31 496 520 
33 563 X 
35 471 754 
37 531 721 
39 436 535 
20 502 1220 
mean 512 718 
S.D. 114 283 





Subj ect Week PGF PGE PGA 
22. AS 17 537 917 
23 414 813 
30 247 452 
34 321 361 
35 293 X 
mean 362 635 
S.D. 115 270 
slope -9.21 -20.72 
sb 
2.23 6.62 
23.DM 22 422 905 380 
30 176 323 570 
31 83 436 517 
33 166 282 292 
35 258 288 254 
36 293 375 391 
38 37 304 1242 
39 391 865 412 
40 112 704 343 




S.D. 134 255 299 
slope 
00 






24. NA 15 78 569 516 
19 96 957 270 
21 216 536 703 
25 132 903 465 
28 165 1005 660 
31 99 517 378 
33 310 851 305 
34 106 505 301 
35 179 648 271 
36 167 594 293 
37 247 588 284 
mean 163 697 404 
S.D. 72 191 160 
slope 4.45 -5.69 -11.63 
sb 
2.81 8.23 5.89 
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Subj ect Week PGF PGE PGA 
25. SH 21 91 919 524 
25 195 1004 401 
29 129 1017 383 
33 337 792 365 
35 86 296 272 
36 119 151 209 
37 120 360 260 
mean 153 648 345 
S.D, 88 367 107 
slope -10.39 -46.6 -14.58 
sb 
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